HC Wainwright Brokers Decrease Earnings Estimates for PTGX

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities researchers at HC Wainwright cut their Q4 2025 earnings estimates for Protagonist Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $0.87 per share for the quarter, down from their prior estimate of $0.88. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.33 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ FY2028 earnings at $2.81 EPS.

A number of other equities research analysts also recently weighed in on the company. JMP Securities reduced their target price on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 7th. Wedbush reissued an “outperform” rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research note on Monday, November 4th. StockNews.com upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. BTIG Research upped their price objective on shares of Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Protagonist Therapeutics from $39.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Protagonist Therapeutics has an average rating of “Buy” and a consensus price target of $53.57.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $42.67 on Wednesday. The stock’s fifty day moving average price is $45.64 and its two-hundred day moving average price is $38.46. The firm has a market cap of $2.54 billion, a PE ratio of 16.00 and a beta of 2.17. Protagonist Therapeutics has a one year low of $15.58 and a one year high of $48.89.

Insider Transactions at Protagonist Therapeutics

In other news, Director William D. Waddill sold 8,000 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the sale, the director now directly owns 12,000 shares in the company, valued at $540,000. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total transaction of $360,000.00. Following the sale, the director now owns 12,000 shares in the company, valued at $540,000. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total value of $631,891.47. Following the completion of the sale, the chief financial officer now owns 34,960 shares of the company’s stock, valued at approximately $1,555,370.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its holdings in shares of Protagonist Therapeutics by 448.9% in the third quarter. BNP Paribas Financial Markets now owns 20,294 shares of the company’s stock valued at $913,000 after purchasing an additional 16,597 shares in the last quarter. FMR LLC boosted its position in shares of Protagonist Therapeutics by 4.5% in the third quarter. FMR LLC now owns 454,196 shares of the company’s stock valued at $20,439,000 after acquiring an additional 19,737 shares during the period. Advantage Alpha Capital Partners LP purchased a new position in Protagonist Therapeutics during the third quarter worth about $510,000. The Manufacturers Life Insurance Company grew its stake in Protagonist Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 115,765 shares of the company’s stock worth $5,209,000 after buying an additional 1,359 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Protagonist Therapeutics in the 3rd quarter worth about $69,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.